Sawai Group Holdings Co Ltd
TSE:4887

Watchlist Manager
Sawai Group Holdings Co Ltd Logo
Sawai Group Holdings Co Ltd
TSE:4887
Watchlist
Price: 2 419 JPY -0.25% Market Closed
Market Cap: ¥279.3B

Relative Value

The Relative Value of one Sawai Group Holdings Co Ltd stock under the Base Case scenario is 2 277.53 JPY. Compared to the current market price of 2 419 JPY, Sawai Group Holdings Co Ltd is Overvalued by 6%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
2 277.53 JPY
Overvaluation 6%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Sawai Group Holdings Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Sawai Group Holdings Co Ltd
TSE:4887
279.4B JPY 1.4 -256.3 19.1 377.9
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
US
Johnson & Johnson
NYSE:JNJ
530.8B USD 5.6 19.8 13.8 17
CH
Roche Holding AG
SIX:ROG
278.2B CHF 4.5 29.5 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
212.8B GBP 5 30.8 20 29.3
CH
Novartis AG
SIX:NOVN
222.3B CHF 5 19.5 15.7 20.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.6 17 11.8 13.7
US
Merck & Co Inc
NYSE:MRK
267.6B USD 4.2 14.1 10 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
147.1B USD 2.3 15 7.6 10.4
FR
Sanofi SA
PAR:SAN
97.2B EUR 1.5 7.1 6.4 6.4
P/E Multiple
Earnings Growth PEG
JP
Sawai Group Holdings Co Ltd
TSE:4887
Average P/E: 23
Negative Multiple: -256.3
23%
N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
US
Johnson & Johnson
NYSE:JNJ
19.8
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.5
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.8
38%
0.8
CH
Novartis AG
SIX:NOVN
19.5
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
17
2%
8.5
US
Merck & Co Inc
NYSE:MRK
14.1
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
27%
0.6
FR
Sanofi SA
PAR:SAN
7.1
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
Sawai Group Holdings Co Ltd
TSE:4887
Average EV/EBITDA: 45.3
19.1
11%
1.7
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
13.8
2%
6.9
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
20
10%
2
CH
Novartis AG
SIX:NOVN
15.7
6%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
1%
11.8
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
6.4
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Sawai Group Holdings Co Ltd
TSE:4887
Average EV/EBIT: 127.8
377.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
37%
1.1
US
Johnson & Johnson
NYSE:JNJ
17
6%
2.8
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
29.3
23%
1.3
CH
Novartis AG
SIX:NOVN
20.2
12%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.7
0%
N/A
US
Merck & Co Inc
NYSE:MRK
11.8
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5
FR
Sanofi SA
PAR:SAN
6.4
15%
0.4